Eu­ro­pean in­vestors pour $156M to beat Blue­stone, Third Rock and RA Cap­i­tal in multi­bil­lion-dol­lar race to the clin­ic

Amid bur­geon­ing ef­forts to cre­ate a new type of cell ther­a­py out of reg­u­la­to­ry T cells — whether by chan­nel­ing or block­ing their im­muno­sup­pres­sive pow­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER